BD-1047 je antagonist sigma receptora koji je selektivan za σ1 tip. Istraživanja na životinjama su pokazala da ovaj ligand potencijalno može da nađe primernu kao antipsihotik i u lečenju neuropatskog bola.[3][4]
- ↑ Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519. edit
- ↑ Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.
- ↑ Skuza G, Rogóz Z (2006). „Effect of BD 1047, a sigma1 receptor antagonist, in the animal models predictive of antipsychotic activity”. Pharmacological Reports : PR 58 (5): 626–35. PMID 17085854.
- ↑ Roh DH, Kim HW, Yoon SY, Seo HS, Kwon YB, Kim KW, Han HJ, Beitz AJ, Na HS, Lee JH (November 2008). „Intrathecal injection of the sigma(1) receptor antagonist BD1047 blocks both mechanical allodynia and increases in spinal NR1 expression during the induction phase of rodent neuropathic pain”. Anesthesiology 109 (5): 879–89. DOI:10.1097/ALN.0b013e3181895a83. PMID 18946301.
